HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increased gastric mucus secretion alleviates non-steroidal anti-inflammatory drug-induced abdominal pain.

Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) can cause dyspeptic symptoms, including abdominal pain. Gastric mucus is important as the first line of defense against luminal irritants. In the present study, we investigated whether gastric mucus secretion could influence the severity of gastric mucosal injuries or NSAID-induced dyspeptic symptoms. Fifteen Helicobacter pylori-negative, healthy males were administered two types of NSAIDs, a non-selective cyclooxygenase inhibitor, naproxen (300 mg, twice a day), or a cyclooxygenase-2-selective inhibitor, etodolac (200 mg, twice a day), for 1 week in a crossover study, with an interval of ≥ 4 weeks. Study participants underwent endoscopic examinations before and after treatment. Pentagastrin-stimulated gastric secretions were collected for 10 min during endoscopic examinations, and were analyzed for gastric acid levels (mEq/10 min) and mucus output (mg hexose/10 min). The grade of gastric mucosal injury was assessed endoscopically. Among 29 subjects who completed the crossover study, 11 individuals reported abdominal pain following the administration of naproxen or etodolac for 1 week, as judged by elevated pain scores, while 18 individuals did not report abdominal pain. The occurrence of symptoms was not associated with the type of NSAIDs administered or the occurrence of erosive injury visualized by endoscopy. Gastric mucus secretion was significantly increased in subjects without drug-induced abdominal pain (P < 0.05), whereas it was significantly reduced in those with drug-induced abdominal pain (P < 0.05). In conclusion, the occurrence of NSAID-induced abdominal pain is associated with reduced levels of gastric mucus secretion rather than the occurrence of endoscopic mucosal injury.
AuthorsToshimitsu Iwabuchi, Katsunori Iijima, Nobuyuki Ara, Tomoyuki Koike, Hirohiko Shinkai, Takafumi Ichikawa, Yayoi Kamata, Kazuhiko Ishihara, Tooru Shimosegawa
JournalThe Tohoku journal of experimental medicine (Tohoku J Exp Med) Vol. 231 Issue 1 Pg. 29-36 (09 2013) ISSN: 1349-3329 [Electronic] Japan
PMID24005244 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Etodolac
  • Naproxen
  • Dinoprostone
Topics
  • Abdominal Pain (chemically induced, pathology)
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects)
  • Dinoprostone (metabolism)
  • Etodolac (administration & dosage, adverse effects)
  • Gastric Mucosa (metabolism)
  • Humans
  • Male
  • Mucus (drug effects, metabolism)
  • Naproxen (administration & dosage, adverse effects)
  • Stomach (drug effects)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: